behenic acid (docosanoic acid)

RN given refers to parent cpd; structure

Also Known As:

docosanoic acid; behenic acid, aluminum salt; behenic acid, barium salt; behenic acid, cadmium salt; behenic acid, ferrium (+3) salt; behenic acid, lithium salt; behenic acid, potassium salt; behenic acid, silver (+1) salt; behenic acid, sodium salt; behenic acid, zinc salt

Networked: 31 relevant articles (0 outcomes, 4 trials/studies)

Bio-Agent Context: Research Results

Lipids: 114793
- Fatty Acids: 27405
  - behenic acid: 31

Experts

1.	Kumar, Neeraj: 1 article (02/2022)
2.	Kumar, Vipin: 1 article (02/2022)
3.	Nath, Virendra: 1 article (02/2022)
4.	Paul, Rakesh Kumar: 1 article (02/2022)
5.	Chen, Jianru: 1 article (01/2022)
6.	Cui, Tingting: 1 article (01/2022)
7.	Du, Pengran: 1 article (01/2022)
8.	King, Irena B: 1 article (01/2022)
9.	Lemaitre, Rozenn N: 1 article (01/2022)
10.	Li, Baizhang: 1 article (01/2022)

Related Diseases

1.	Type 2 Diabetes Mellitus (MODY) 01/01/2020 - "Very-long-chain SFAs (VLCSFAs), such as arachidic acid (20:0), behenic acid (22:0), and lignoceric acid (24:0), have demonstrated inverse associations with cardiometabolic conditions, although more evidence is needed to characterize their relation with risk of type 2 diabetes (T2D). " 11/01/2023 - "A unique group of circulating very-long-chain saturated fatty acids (VLCSFAs), including arachidic acid (20:0), behenic acid (22:0), and lignoceric acid (24:0), have been associated with a lower risk of type 2 diabetes, although associations with early metabolic risk phenotypes preceding type 2 diabetes have received limited study. " 01/01/2022 - "In contrast to other saturated fatty acids, very long-chain saturated fatty acids (VLSFAs) have received limited attention The purpose of this review is to summarize the associations of VLSFAs, including arachidic acid, behenic acid, and lignoceric acid, with cardiovascular disease outcomes and type 2 diabetes; to discuss the findings implications; and to call for future studies of the VLSFAs. " 10/01/2014 - "By contrast, measured odd-chain SFAs (15:0 [pentadecanoic acid] and 17:0 [heptadecanoic acid]) were inversely associated with incident type 2 diabetes (HR [95% CI] per 1 SD difference: 0·79 [0·73-0·85] for pentadecanoic acid and 0·67 [0·63-0·71] for heptadecanoic acid), as were measured longer-chain SFAs (20:0 [arachidic acid], 22:0 [behenic acid], 23:0 [tricosanoic acid], and 24:0 [lignoceric acid]), with HRs ranging from 0·72 to 0·81 (95% CIs ranging between 0·61 and 0·92). " 01/01/2022 - "Random-effects or fixed-effects models was used to estimate the pooled relative risks (RRs) and corresponding 95% confidence intervals (CIs) for the association of total or individual SFA biomarkers, including even-chain SFAs (e.g., 14:0, myristic acid; 16:0, palmitic acid; 18:0, stearic acid), odd-chain SFAs (e.g., 15:0, pentadecanoic acid; 17:0, margaric acid) and very-long-chain SFAs (VLCSFAs; e.g., 20:0, arachidic acid; 22:0, behenic acid; 24:0, lignoceric acid), with risk of incident type 2 diabetes (T2D), cardiovascular disease [CVD; coronary heart disease (CHD) inclusive of stroke], CHD and stroke. "
2.	Cardiovascular Diseases (Cardiovascular Disease) 01/01/2022 - "In contrast to other saturated fatty acids, very long-chain saturated fatty acids (VLSFAs) have received limited attention The purpose of this review is to summarize the associations of VLSFAs, including arachidic acid, behenic acid, and lignoceric acid, with cardiovascular disease outcomes and type 2 diabetes; to discuss the findings implications; and to call for future studies of the VLSFAs. " 01/01/2022 - "Random-effects or fixed-effects models was used to estimate the pooled relative risks (RRs) and corresponding 95% confidence intervals (CIs) for the association of total or individual SFA biomarkers, including even-chain SFAs (e.g., 14:0, myristic acid; 16:0, palmitic acid; 18:0, stearic acid), odd-chain SFAs (e.g., 15:0, pentadecanoic acid; 17:0, margaric acid) and very-long-chain SFAs (VLCSFAs; e.g., 20:0, arachidic acid; 22:0, behenic acid; 24:0, lignoceric acid), with risk of incident type 2 diabetes (T2D), cardiovascular disease [CVD; coronary heart disease (CHD) inclusive of stroke], CHD and stroke. "
3.	Cognitive Dysfunction 01/01/2020 - "The objective of this study was to assess the associations of plasma phospholipid VLSFAs [arachidic acid (20:0), behenic acid (22:0), tricosanoic acid (23:0), and lignoceric acid (24:0)] with 20-y cognitive decline in the Atherosclerosis Risk in Communities (ARIC) participants. "
4.	Atherosclerosis 01/01/2020 - "The objective of this study was to assess the associations of plasma phospholipid VLSFAs [arachidic acid (20:0), behenic acid (22:0), tricosanoic acid (23:0), and lignoceric acid (24:0)] with 20-y cognitive decline in the Atherosclerosis Risk in Communities (ARIC) participants. "
5.	Diabetes Mellitus 02/28/2022 - "Identification of behenic acid as medicinal food for the diabetes mellitus: structure-based computational approach and molecular dynamics simulation studies." 02/28/2022 - "Behenic acid is present in different parts of the Moringa tree and may serve as medifood in type II diabetes mellitus."

Related Drugs and Biologics

1.	lignoceric acid (tetracosanoic acid)
2.	arachidic acid
3.	Fatty Acids (Saturated Fatty Acids)
4.	tricosanoic acid
5.	Phospholipids (Phosphatides)
6.	hexacosanoic acid
7.	Acids
8.	Palmitic Acid (Hexadecanoic Acid)
9.	pentadecanoic acid
10.	Myristic Acid (Tetradecanoic Acid)